Randomized, placebo-controlled, phase III surgical adjuvant clinical trial of megestrol acetate (Megace) in selected patients with malignant melanomaMARKOVIC, Svetomir; SUMAN, Vera J; KROOK, James E et al.American journal of clinical oncology. 2002, Vol 25, Num 6, pp 552-556, issn 0277-3732, 5 p.Article

On the design of the phase III drug trial. The example of rheumatoid arthritisHADLER, N. M; GILLINGS, D. B.Arthritis and rheumatism. 1983, Vol 26, Num 11, pp 1354-1361, issn 0004-3591Article

Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: Final report of RTOG 9404PRADOS, Michael D; SEIFERHELD, Wendy; GREENBERG, Harry S et al.International journal of radiation oncology, biology, physics. 2004, Vol 58, Num 4, pp 1147-1152, issn 0360-3016, 6 p.Article

The ethical position of the attending physician in phase III of clinical investigationsVON EICKSTEDT, K.-W.International journal of clinical pharmacology, therapy and toxicology (1980). 1983, Vol 21, Num 10, pp 529-534, issn 0174-4879Article

MR angiography of aortoiliac occlusive disease : A phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325GOYEN, Mathias; EDELMAN, Mark; KENT YUCEL, E et al.Radiology. 2005, Vol 236, Num 3, pp 825-833, issn 0033-8419, 9 p.Article

What are the reasons for negative phase III trials of molecular-target-based drugs?SAIJO, Nagahiro.Cancer science. 2004, Vol 95, Num 10, pp 772-776, issn 1347-9032, 5 p.Article

Inference of Unexpected Genetic Relatedness among Individuals in HapMap Phase IIIPEMBERTON, Trevor J; CHAOLONG WANG; LI, Jun Z et al.American journal of human genetics. 2010, Vol 87, Num 4, pp 457-464, issn 0002-9297, 8 p.Article

The importance of reporting patient recruitment details in phase III trialsWRIGHT, James R; BOUMA, Sarah; DAYES, Ian et al.Journal of clinical oncology. 2006, Vol 24, Num 6, pp 843-847, issn 0732-183X, 5 p.Article

Phase III Clinical Trial Development: A Process of Chutes and LaddersDILTS, David M; CHENG, Steven K; CRITES, Joshua S et al.Clinical cancer research (Print). 2010, Vol 16, Num 22, pp 5381-5389, issn 1078-0432, 9 p.Article

Using a drug before the risks and benefits are known from a phase 3 clinical trial : Thoughts on compassionMILLER, Joan W.Archives of ophthalmology (1960). 2006, Vol 124, Num 7, pp 1029-1031, issn 0003-9950, 3 p.Article

Accrual Experience of National Cancer Institute Cooperative Group Phase III Trials Activated From 2000 to 2007KORN, Edward L; FREIDLIN, Boris; MOONEY, Margaret et al.Journal of clinical oncology. 2010, Vol 28, Num 35, pp 5197-5201, issn 0732-183X, 5 p.Article

The benefits of participation in clinical trialsVAN DONGEN, J. A; VAN DE VELDE, C. J. H.European journal of surgical oncology. 1996, Vol 22, Num 6, pp 561-562, issn 0748-7983Article

Disclosure of competing financial interests and role of sponsors in phase III cancer trialsTUECH, Jean-Jacques; MOUTEL, Grégoire; PESSAUX, Patrick et al.European journal of cancer (1990). 2005, Vol 41, Num 15, pp 2237-2240, issn 0959-8049, 4 p.Article

Phase III Clinical Trials That Integrate Treatment and Biomarker EvaluationFREIDLIN, Boris; ZHUOXIN SUN; GRAY, Robert et al.Journal of clinical oncology. 2013, Vol 31, Num 25, pp 3158-3161, issn 0732-183X, 4 p.Article

Time to mandate data release and independent audits for all clinical trialsHAINES, Ian E; GABOR MIKLOS, George L.Medical journal of Australia. 2011, Vol 195, Num 10, pp 575-577, issn 0025-729X, 3 p.Article

Responsiveness of NEI VFQ-25 to Changes in Visual Acuity in Neovascular AMD: Validation Studies from Two Phase 3 Clinical TrialsSUNER, Ivan J; KOKAME, Gregg T; YU, Elaine et al.Investigative ophthalmology & visual science. 2009, Vol 50, Num 8, pp 3629-3635, issn 0146-0404, 7 p.Article

Peut-on prédire la bonne posologie de la phase III ? = Ho<w to predict the therapeutic dose range to be tested in phase III clinical trials?DAHAN, R; JAILLON, P; LEHNER, J. P et al.Thérapie (Paris). 1993, Vol 48, Num 4, pp 297-301, issn 0040-5957Conference Paper

Locoregionally advanced carcinoma of the oropharynx: Conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy: A multicenter randomized trialOLMI, Patrizia; CRISPINO, Sergio; COLOMBO, Alessandro et al.International journal of radiation oncology, biology, physics. 2003, Vol 55, Num 1, pp 78-92, issn 0360-3016, 15 p.Article

PIPERACILLIN SODIUM (A PHASE III CLINICAL TRIAL)MACBETH WAAG.1981; J. INT. MED. RES.; ISSN 0300-0605; GBR; DA. 1981; VOL. 9; NO 5; PP. 353-359; BIBL. 1 REF.Article

Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991EGGERMONT, Alexander M. M; SUCIU, Stefan; DUMMER, Reinhard et al.European journal of cancer (1990). 2012, Vol 48, Num 2, pp 218-225, issn 0959-8049, 8 p.Article

Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological responseVINGERHOETS, Johan; RIMSKY, Laurence; VAN EYGEN, Veerle et al.Antiviral therapy (London). 2013, Vol 18, Num 2, pp 253-256, issn 1359-6535, 4 p.Article

Design Issues in Randomized Phase II/III TrialsKORN, Edward L; FREIDLIN, Boris; ABRAMS, Jeffrey S et al.Journal of clinical oncology. 2012, Vol 30, Num 6, pp 667-671, issn 0732-183X, 5 p.Article

Efficacy and Safety of the Betamethasone Valerate 0.1% Plaster in Mild-to-Moderate Chronic Plaque Psoriasis: A Randomized, Parallel-Group, Active-Controlled, Phase III StudyNALDI, Luigi; YAWALKAR, Nikhil; KASZUBA, Andrzej et al.American journal of clinical dermatology. 2011, Vol 12, Num 3, pp 191-201, issn 1175-0561, 11 p.Article

Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III studyHEE CHUL EUN; OH SANG KWON; HWA YOUNG PARK et al.Journal of the American Academy of Dermatology. 2010, Vol 63, Num 2, pp 252-258, issn 0190-9622, 7 p.Article

Phase II/III randomized trial of TCH346 in patients with ALSMILLER, R; BRADLEY, W; STRONG, M et al.Neurology. 2007, Vol 69, Num 8, pp 776-784, issn 0028-3878, 9 p.Article